Table 1 Clinicopathological characteristics of the patients according to the CyCAR criteria at baseline status (CTC1) and VEGFR status
CTC 1 | CTC 1 VEGFR | |||||
|---|---|---|---|---|---|---|
N (%) − | N (%) + | p | N (%) − | N (%) + | p | |
Age (years) | ||||||
< 55 | 15 (62.5%) | 9 (37.5%) | 0.622 | 3 (33.3%) | 6 (66.7%) | 1.00 |
≥ 55 | 29 (54.7%) | 24 (45.3%) | 7 (29.2%) | 17 (70.8%) | ||
Gender | ||||||
Male | 30 (58.2%) | 21 (41.2%) | 0.808 | 9 (40.9%) | 13 (59.1%) | 0.144 |
Female | 14 (53.9%) | 12 (46.1%) | 2 (16.7%) | 10 (83.3%) | ||
Primary tumor location | ||||||
Colon | 25 (54.4%) | 21 (45.6%) | 0.641 | 5 (23.8%) | 16 (76.2%) | 0.164 |
Rectum | 19 (61.3%) | 12 (38.7%) | 6 (46.2%) | 7 (53.8%) | ||
Metastasis surgery | ||||||
No | 32 (57.1%) | 24 (42.9%) | 1.00 | 8 (32%) | 17 (68%) | 0.625 |
Yes | 12 (57.1%) | 9 (42.9%) | 3 (33.3%) | 6 (66.7%) | ||
Primary tumor surgery | ||||||
No | 21 (75%) | 7 (25%) | 0.019* | 4 (57.1%) | 3 (42.9%) | 0.132 |
Yes | 23 (46.9%) | 26 (53.1%) | 7 (25.9%) | 20 (74.1%) | ||
Synchronous metastasis | ||||||
No | 3 (25%) | 9 (75%) | 0.024* | 2 (22.2%) | 7 (77.8%) | 0.686 |
Yes | 41 (63.1%) | 24 (36.9%) | 8 (33.3%) | 16 (66.7%) | ||
K-RAS | ||||||
Mutated | 25 (69.4%) | 11 (30.6%) | 0.061 | 4 (36.4%) | 7 (63.6%) | 0.546 |
Wild-type | 18 (46.2%) | 21 (53.8%) | 7 (31.8%) | 22 (68.2%) | ||
Basal CEA | ||||||
Standard | 6 (40%) | 9 (60%) | 0.153 | 2 (20%) | 8 (80%) | 0.339 |
High | 37 (61.7%) | 23 (38.3%) | 8 (34.8%) | 15 (65.2%) | ||
Basal Ca 19.9 | ||||||
Standard | 19 (46.3%) | 22 (53.7%) | 0.034* | 7 (31.8%) | 15 (68.2%) | 0.627 |
High | 23 (71.9%) | 9 (28.1%) | 3 (30%) | 7 (70%) | ||
Progression | ||||||
Yes | 28 (53.8%) | 24 (46.2%) | 0.485 | 7 (29.2%) | 17 (70.8%) | 0.634 |
No | 9 (64.3%) | 5 (35.7%) | 2 (40%) | 3 (60%) | ||
Survival | ||||||
Yes | 18 (60%) | 12 (40%) | 1.00 | 3 (25%) | 9 (75%) | 0.683 |
No | 22 (61.1%) | 14 (38.9) | 5 (35.7%) | 9 (64.3%) | ||
RECIST 12 weeks | ||||||
Favorable | 31 (53.4%) | 27 (46.6%) | 0.402 | 7 (25.9%) | 20 (74.1%) | 0.557 |
Adverse | 3 (75%) | 1 (25%) | 0 (0%) | 1 (100%) | ||
RECIST 24 weeks | ||||||
Favorable | 19 (52.8%) | 17 (47.2%) | 0.376 | 4 (23.5%) | 13 (76.5%) | 0.468 |
Adverse | 5 (38.5%) | 8 (61.5%) | 3 (37.5%) | 5 (62.5%) | ||
CyCAR 12 weeks | ||||||
Favorable | 29 (65.9%) | 15 (34.1%) | 0.087 | 4 (26.7%) | 11 (73.3%) | 1.00 |
Adverse | 7 (38.9%) | 11 (61.1%) | 3 (27.3%) | 8 (72.7%) | ||
CyCAR 24 weeks | ||||||
Favorable | 30 (55.6%) | 24 (44.4%) | 0.537 | 7 (29.2%) | 17 (70.8%) | 0.574 |
Adverse | 8 (66.7%) | 4 (33.3%) | 2 (50%) | 2 (50%) | ||